Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PdC +/- Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT01665794Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Aug 2012
- Primary completion
- Nov 2025
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of carfilzomib and daratumumab in multiple myeloma (MM) (2 arms), sponsored by University of Chicago. Primary endpoints: Maximum tolerated dose at 28 days, Partial response rate at 4 months and 1 more. Started Aug 2012; status: completed.
02
Drugs
carfilzomibdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01665794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01665794.